Company Filing History:
Years Active: 2023
Title: Innovations of Thomas Payne
Introduction
Thomas Payne is a notable inventor based in Cambridge, GB, recognized for his contributions to the field of cellular reprogramming and gene therapy. With a total of two patents to his name, he has made significant strides in advancing scientific knowledge and technology.
Latest Patents
One of his latest patents is titled "Methods for nuclear reprogramming using synthetic transcription factors." This invention provides methods for reprogramming mammalian somatic cells by regulating the expression of endogenous cellular genes. The process involves activating the transcription of embryonic stem cell-associated genes, such as oct3/4, while suppressing the transcription of somatic cell-specific and cell death-associated genes. The use of synthetic transcription factors allows for faster and more efficient nuclear reprogramming, which is crucial for clinical and commercial applications. Additionally, the patent includes therapeutic methods for using cells obtained from these techniques for the treatment of diseases amenable to stem cell therapy.
Another significant patent by Thomas Payne is focused on "CRISPR-associated (Cas) proteins with reduced immunogenicity." This invention outlines methods for reducing the immunogenicity of Cas proteins and the modified proteins produced from these methods. It also encompasses techniques for cell and gene therapy, including genetic modifications and alterations of gene expression made in-vivo or ex-vivo using the modified Cas proteins.
Career Highlights
Throughout his career, Thomas Payne has worked with prominent companies such as Lonza Inc. and Lonza Walkersville, Inc. His work in these organizations has contributed to the development of innovative solutions in biotechnology and pharmaceuticals.
Collaborations
Thomas has collaborated with esteemed colleagues, including Jesús Zurdo and Noel Hillier Smith, to further enhance his research and inventions.
Conclusion
Thomas Payne's innovative work in cellular reprogramming and gene therapy has the potential to revolutionize medical treatments and improve patient outcomes. His patents reflect a commitment to advancing science and technology in meaningful ways.